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Objectives: Individuals with bipolar disorder have high rates of other
medical comorbidity, which is associated with higher mortality rates and
worse course of illness. The present study examined common predictors
of medical comorbidity.
Methods: The Clinical and Health Outcomes Initiative in Comparative
Eﬀectiveness for Bipolar Disorder study (Bipolar CHOICE) enrolled 482
participants with bipolar I or bipolar II disorder in a six-month,
randomized comparative eﬀectiveness trial. Baseline assessments
included current and lifetime DSM-IV-TR diagnoses, demographic
information, psychiatric and medical history, severity of psychiatric
symptoms, level of functioning, and a fasting blood draw. Medical
comorbidities were categorized into two groups: cardiometabolic (e.g.,
diabetes, hyperlipidemia, and metabolic syndrome) and non-
cardiovascular (e.g., seizures, asthma, and cancer). Additionally, we
looked at comorbid substance use (e.g., smoking and drug dependence).
Results: We found that 96.3% of participants had at least one other
medical comorbidity. Older age predicted a greater likelihood of having
a cardiometabolic condition. Early age of onset of bipolar symptoms
was associated with a lower chance of having a cardiometabolic
condition, but a greater chance of having other types of medical
comorbidity. Additional predictors of other medical comorbidities in
bipolar disorder included more time spent depressed, less time spent
manic/hypomanic, and longer duration of illness. Medications
associated with weight gain were associated with low high-density
lipoprotein and abnormal triglycerides.
Conclusions: There appears to be a substantial medical burden
associated with bipolar disorder, highlighting the need for collaborative
care among psychiatric and general medical providers to address both
psychiatric and other medical needs concomitantly in this group of
patients.
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Individuals with bipolar disorder have high
rates of medical comorbidities in addition to
chronic, debilitating mood symptoms and
impairments in functioning (1–5). Previous stud-
ies have found that over 50% of individuals
with bipolar disorder have at least one medical
comorbidity (6–8); patients are at increased risk
for cardiovascular disease (9–13), respiratory
disorders (14, 15), thyroid disease (16), hepatitis
C (17), type-2 diabetes (18), and obesity (19,
20), as compared to rates in the general popula-
tion. This medical burden in bipolar disorder is
associated with a higher rate of morbidity and
mortality (21–23) and a 30% shorter life expec-
tancy (24). It is also associated with increased
costs of medical care and loss of productivity
(25), worse course of bipolar illness (i.e., more
episodes, longer duration of episode, and poor
functioning) (6, 26–29), and higher rates of
treatment with psychotropic medications (6).
Moreover, medications commonly prescribed to
treat bipolar disorder can exacerbate risks of
metabolic disturbances (30, 31) and cardiovascu-
lar disease (32–34).
Given the negative impact of this substantial
medical burden in bipolar disorder, it is vital to
understand what features of bipolar disorder
contribute to this increased risk of comorbidity.
Extant research in bipolar disorder has limited
generalizability, as it has tended to be focused
only on a few possible medical conditions (17,
35) or on speciﬁc subgroups, such as elderly peo-
ple (36, 37), or homogenous samples (15, 27).
Thus, the aim of the present study was to assess
the rates of diﬀerent comorbidities in a large,
heterogeneous sample of individuals with bipolar
disorder, and to assess demographic and clinical
predictors of such comorbidity. We expected that
rates of comorbid cardiometabolic conditions
(e.g., type 2 diabetes) and other medical comor-
bidities (e.g., asthma and cancer) would not dif-
fer by bipolar subtype, but that worse course of
illness (i.e., longer duration, more frequent mood
episodes, and poor functioning) and earlier age
of onset would be associated with an increased
likelihood of having medical comorbidities. We
also expected that medications known to induce
weight gain would be associated with greater
metabolic disturbances.
Materials and methods
Procedures
The Clinical and Health Outcomes Initiative in
Comparative Eﬀectiveness for Bipolar Disorder
study (Bipolar CHOICE) (38) was a six-month,
multi-site, randomized comparative eﬀectiveness
trial comparing a classic mood stabilizer (lithium)
to a common antipsychotic used to treat bipolar
disorder (quetiapine). Study physicians were able
to prescribe additional medications as needed
(although antipsychotics were excluded in patients
randomized to lithium, and other antipsychotics
and lithium were excluded in patients randomized
to quetiapine) as long as medications were consis-
tent with the guidelines used to treat bipolar disor-
der (39) and personalized to the needs of the
patient (40). The rationale, design, and methods of
Bipolar CHOICE are reported elsewhere (38). The
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present study examined data from the baseline visit
(see Fig. 1).
Participants
The Institutional Review Boards of the 11 sites
approved the study protocol. Bipolar CHOICE
enrolled 482 individuals between the ages of 18
and 68 years. Limited inclusion and exclusion cri-
teria were designed to maximize heterogeneity of
the sample and hence generalizability of results
(38), but participants were required to have a
DSM-IV-TR bipolar I or bipolar II diagnosis and
be at least mildly symptomatic [Clinical Global
Impression Scale for Bipolar Disorder (CGI-
BP) ≥ 3] at study entry.
Psychiatric and substance use diagnoses were
determined using the extended Mini-International
Neuropsychiatric Interview, an electronic version
of a validated structured diagnostic interview (41).
The CGI-BP assessed bipolar illness severity on
three separate subscales for mania, depression, and
overall bipolar illness, ranging from 1 to 7 (normal
to very severely ill) (42). Psychiatric symptom
severity and overall functioning and life satisfac-
tion were measured with the Bipolar Inventory of
Symptoms Scale (BISS) (43, 44) and LIFE-Range
of Impaired Functioning Tool (LIFE-RIFT) (45),
respectively. Clinical interviews obtained demo-
graphic information, psychiatric/medical history
(e.g., asthma, myocardial infarction, and hepatitis)
and current medications. A fasting blood draw was
also conducted to assess cardiometabolic variables
such as levels of triglycerides and cholesterol.
Statistical analyses
Medical comorbidities were divided into two
groups to understand speciﬁc trends in the condi-
tions associated with bipolar disorder: (Group 1)
cardiometabolic disturbances (coronary artery dis-
ease, myocardial infarction, diabetes, hyperglyce-
mia, hyperlipidemia, hypercholesterolemia,
triglyceridemia, and metabolic syndrome); (Group
2) non-cardiovascular conditions (kidney disease,
seizures, thyroid disease, asthma, migraines, can-
cer, hepatitis, and head trauma). Comorbid sub-
stance use (smoking, alcohol and drug abuse/
dependence) was also included in the analyses. The
rationale for these groupings was that we expected
cardiometabolic disorders and substance use to be
particularly associated with the course of bipolar
disorder (6).
Predictors of medical comorbidity were tested
using chi-square tests for categorical variables and
t-tests for continuous variables. If an overall chi-
square was signiﬁcant, we used logistic regression
to determine speciﬁc contrasts of interest. The pri-
mary analysis assessed the association of medical
disorders with demographic characteristics and
clinical features of bipolar disorder. Analyses
involving number of lifetime depressive/manic epi-
sodes and total number of years depressed/manic
were adjusted for age. All predictors were then
considered for entry into multivariate models
using stepwise logistic regression to evaluate
which variables uniquely predicted medical com-
orbidity. Finally, we assessed whether reported
use of medications known to induce weight gain
Consent/screen 
(N = 692) 
Randomized 
(N = 482) 
Reasons not randomized: 
 Ineligible (n = 116) 
 Cannot commit to study requirements 
or noncompliant (n = 43) 
 Withdrew consent (n = 17) 
 Required higher level of care (n = 20) 
 Other (n = 14) 
QTP + APT 
(n = 242) 
Li + APT 
(n = 240) 
Completed 
n = 182 (75.21%) 
Exited 
n = 60 (24.79%) 
Completed 
n = 182 (75.83%) 
Exited 
n = 58 (24.17%) 
Reasons for exit: 
 Withdrew consent (n = 13) 
 Lost to follow-up (n = 35) 
 Noncompliant (n = 6) 
 SAE (n = 2) 
 Death (n = 0) 
 Other (n = 4) 
On procedure 
n = 150 (82.42%) 
Off procedure 
n = 32 (17.58%) 
QTP monotherapy 
n = 53 (35.33%) 
On procedure 
n = 134 (73.63%) 
Off Procedure 
n = 48 (26.37%) 
Li monotherapy 
n = 42 (31.34%) 
Fig. 1. CONSORT chart. APT = antipsychotic; Li = lithium; QTP = quetiapine; SAE = serious adverse event.
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(lithium, valproate, clomipramine, imipramine,
amitriptyline, mirtazapine, clozapine, olanzapine,
quetiapine, or risperidone) correlated with cardio-
metabolic disturbances at baseline.
Results
Demographic and clinical features are reported in
Table 1. In this sample, we found that 96.3% of
participants met criteria for at least one medical
Table 1. Baseline demographic and clinical measures in the Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder
study (Bipolar CHOICE)
Characteristic
Overall
(n = 482)
Li + APT
(n = 240)
QTP + APT
(n = 242) p-value
Female, % 58.7 58.3 59.1 0.87
Age, years, mean  SD 38.9  12.1 38.6  12.1 39.1  12.2 0.63
Race, %
White 72.2 72.5 71.9 0.83
Black 19.9 19.2 20.7
Asian 3.3 3.8 2.9
Other 4.6 4.6 4.5
Ethnicity: Hispanic or Latino, % 11.0 13.3 8.7 0.09
Education, %
Less than high school 5.0 5.0 5.0 0.85
High school or GED 20.3 18.3 22.3
Some college 30.9 30.0 31.8
Technical school or associate degree 12.0 12.9 11.2
College diploma 24.3 25.8 22.7
Graduate or professional degree 7.5 7.9 7.0
Employment status, %
Employed 36.3 39.2 33.5 0.56
Unemployed 35.3 32.9 37.6
Disability recipient 15.4 15.8 14.9
Student 9.1 7.5 10.7
Retired 1.7 2.1 1.2
Other 2.3 2.5 2.1
Bipolar I disorder, % 68.3 66.7 69.8 0.46
History of psychiatric hospitalizations, % 46.8 45.6 47.9 0.61
History of suicide attempts, %a 36.1 36.3 36.0 0.94
Any substance use disorder (lifetime), %b 61.4 62.1 60.7 0.76
Any anxiety disorder (current), %c 57.5 55.4 59.5 0.36
Age (years) of first, mean  SD:
Depressive episode 16.4  8.0 16.0  8.6 16.7  7.5 0.36
Manic episode 19.8  9.5 19.5  9.8 20.1  9.1 0.47
Mood episode 15.5  7.7 15.1  8.3 16.0  7.1 0.17
Duration (years) of, mean  SD:
Depression 22.5  12.3 22.6  12.3 22.4  12.3 0.90
Mania 19.0  12.2 19.1  12.1 18.9  12.3 0.92
Illness 23.3  12.4 23.6  12.5 23.1  12.4 0.70
BISS total score, mean  SD
Overall 56.1  18.8 55.7  18.8 56.5  19.0 0.67
Depression 37.6  14.0 38.0  13.4 37.2  14.6 0.53
Mania 18.5  12.1 17.8  12.1 19.3  12.1 0.16
CGI-BP severity score, mean  SD 4.5  0.9 4.5  0.8 4.5  0.9 0.83
MADRS score, mean  SD 23.8  10.3 24.2  10.0 23.5  10.6 0.44
YMRS score, mean  SD 13.4  8.7 13.0  8.9 13.8  8.6 0.33
Statistics reported are % (n/N) for categorical variables and mean  standard deviation (SD) (N) for continuous variables. p-values
reported are based on chi-square test for categorical variables and t-test for continuous variables.
APT = antipsychotic; BISS = Bipolar Inventory of Symptoms Scale; CGI-BP = Clinical Global Impressions for Bipolar Disorder; GED =
General Educational Development; Li = lithium; MADRS = Montgomery–Asberg Depression Rating Scale; QTP = quetiapine; YMRS =
Young Mania Rating Scale.
aBased on the Columbia Suicide Severity Rating Scale, a scale used to assess recent and lifetime suicide-related thoughts and behav-
iors (59).
bIncludes patients with any current alcohol/drug abuse/dependence [based on the Mini-International Neuropsychiatric Interview
(MINI)].
cIncludes patients with any one of the following current diagnoses (based on the MINI): panic disorder, agoraphobia, social phobia, and
generalized anxiety disorder.
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comorbidity, 71.2% for at least one cardiometa-
bolic disturbance (Group 1), 56.2% for at least one
other non-cardiometabolic, medical comorbidity
(Group 2), and 80.5% for substance use (Group 3).
Notably, more than 70% of participants reported
being current or past smokers. Substance use was
more prevalent in bipolar I than bipolar II disorder
(Table 2).
Older participants were more likely to have a
Group 1 condition. A later age of onset, more
depressive symptoms, and fewer manic symp-
toms at baseline were associated with a higher
likelihood of having a Group 1 disorder. Spend-
ing more time in the past year manic/hypomanic
and current manic/hypomanic symptoms (BISS)
corresponded to a decreased likelihood of hav-
ing a Group 1 disorder, such that a 20%
increase in time spent manic/hypomanic
decreased the odds of a Group 1 disorder by
23% (Table 3). For each 20% increase in time
depressed in the last year (e.g., from 0–20% to
20–40%), the odds of a Group 1 disorder
increased by 18%, though the eﬀect was margin-
ally signiﬁcant (p = 0.069).
Female gender, greater percentage of time spent
depressed, presence of lifetime substance use disor-
der, younger age of illness onset, and longer
duration of illness (even when controlling for parti-
cipants’ age) predicted Group 2 conditions
(Tables 3 and 4). When controlling for age, partici-
pants who reported spending a larger percentage
of the past year depressed were more likely to have
at least one Group 2 condition. Each 20% increase
in time depressed elevated the odds of a Group 2
disorder by 23%.
The likelihood of meeting criteria for substance
use (Group 3) was signiﬁcantly associated with
race, lower household income, older age, lower
education level, comorbid anxiety disorder diagno-
sis, and worse depression and life functioning
(LIFE-RIFT) as well as greater illness severity
(CGI-BP overall and depression; percentage of
past year spent depressed) (Tables 3 and 4). Fol-
low-up tests showed that Asians had 27% lower
odds of substance use than non-Asians. Finally,
medications associated with weight gain were asso-
ciated with low high-density lipoprotein (HDL)
cholesterol and abnormal (high) triglycerides
(Table 5).
In our multivariate models (i.e., each variable is
adjusted for all other covariates in the model), we
found that older age and less severe manic symp-
toms remained associated with the presence of
Group 1 conditions [95% conﬁdence interval
(CI): 1.03–1.07, p < 0.001; 95% CI: 0.91–0.97,
p < 0.001, respectively]. In Group 2, female gen-
Table 2. Prevalence of individual medical conditions and categories
of conditions and differences between bipolar I and bipolar II disorder
subtypes
Overall
(n = 482)
Bipolar I
(n = 329)
Bipolar II
(n = 153)
p-value
(v2-test)
Group 1
Hypertension 18.7 19.1 17.8 0.72
Coronary artery
disease/
myocardial
infarction
1.2 0.9 2.0 0.33
Diabetes 6.2 6.4 5.9 0.83
Hyperglycemia 14.5 14.0 15.7 0.62
Hyperlipidemia 21.4 19.8 24.8 0.21
High total
cholesterol
12.7 13.8 10.5 0.32
Low HDL 32.8 33.9 30.3 0.42
High LDL 28.1 28.9 26.5 0.59
Abnormal
triglycerides
28.4 27.8 29.6 0.69
Metabolic
syndrome
27.3 26.6 28.9 0.61
Any Group 1 71.2 72.3 68.6 0.40
Group 2
Kidney disease 2.7 3.0 2.0 0.50
Seizures 5.0 6.1 2.6 0.10
Thyroid disease 4.6 4.0 5.9 0.34
Asthma 20.1 20.4 19.6 0.85
Migraines 28.5 26.2 33.3 0.11
Cancer 4.4 3.3 6.5 0.11
Hepatitis 4.0 5.8 0 0.002
Head trauma 16.2 17.0 14.4 0.46
Any Group 2 56.2 55.6 57.5 0.70
Group 3 (substance use)
Current smoker 51.8 56.7 41.2% 0.001
Ever smoker 72.4 76.6 63.4% 0.003
Alcohol
dependence
(lifetime)
34.3 39.0 24.2% 0.001
Drug
dependence
(lifetime)
36.2 42.7 22.2% <0.001
Any Group 3 80.5 85.4 69.9% <0.001
Any Group
1, 2, or 3
96.3 96.7 95.4% 0.51
Values are reported as %. Criteria were based on either medical
history or laboratory values. Hyperglycemia was defined as
being present if fasting blood glucose ≥100 mg/dL; high total
cholesterol if total cholesterol ≥240 mg/dL; low high-density lipo-
protein cholesterol (HDL-C) if HDL-C <50 mg/dL (female) or
<40 mg/dL (male); high low-density lipoprotein cholesterol
(LDL-C) if LDL-C ≥130 mg/dL; high triglycerides if triglycerides
≥150 mg/dL; metabolic syndrome if three or more of the follow-
ing criteria were met: waist circumference >35 inches (female)
or >40 inches (male), triglycerides ≥ 150 mg/dL, HDL-
C <50 mg/dL (female) or <40 mg/dL (male) or participant on
medications for hypercholesterolemia, systolic blood pressure
<130 mm Hg or diastolic blood pressure >85 mm Hg or partici-
pant on medications for hypertension, or fasting blood glucose
≥100 mg/dL or participant on medications for diabetes.
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der, presence of a lifetime substance use disorder,
younger age of illness onset, and longer illness
duration remained as predictors of Group 2 condi-
tions (all p < 0.05). Finally, lower household
income (v2 = 15.72, p < 0.001) and higher manic
severity (CGI mania) predicted substance use
(95% CI: 1.02–1.63, p < 0.035), with older age
marginally predicting substance use (95% CI:
1.00–1.05, p = 0.062).
Discussion
This study is consistent with previous data demon-
strating high rates of medical comorbidity in bipo-
lar disorder (11, 13, 46), but extends these data by
highlighting speciﬁc associations among these con-
ditions with speciﬁc demographic and clinical fea-
tures. For example, a complicated association of
age and age of bipolar illness onset with medical
comorbidity. Consistent with ﬁndings for non-
bipolar samples, the likelihood of having a cardio-
metabolic condition (Group 1) as well as substance
use increased with age (47, 48) which remained sig-
niﬁcant in the multivariate models; however, this
ﬁnding did not hold for other, non-cardiovascular
medical conditions (Group 2). This may suggest
that, with age, bipolar patients are susceptible to
developing cardiometabolic disease and substance
problems, or conditions associated with unhealthy
lifestyle choices, but not necessarily other medical
conditions. This ﬁnding may also be explained by
migraines and asthma having early ages of onset as
they were the most prevalent Group 2 conditions
(49–51).
We found that an earlier age of onset and longer
duration of illness, independent of age and other
variables, predicted having a Group 2 condition
(which remained signiﬁcant in the multivariate
analyses) and later age of onset was associated
with a greater likelihood of having a Group 1 con-
dition. Thus, perhaps cardiometabolic conditions
that develop with age (as discussed above) could
trigger a later onset of bipolar disorder, as these
medical conditions are risk factors for depressive
symptoms and mood episodes (27, 52, 53). Alter-
natively, perhaps Group 1, cardiometabolic condi-
tions and substance use, or those most modiﬁable,
become the focus of treatment instead of psychiat-
ric conditions, such as bipolar disorder, resulting
in later detection or age of onset. Similarly, low
income was associated with substance use, present-
ing another potential barrier to diagnosis or treat-
ment. Further research is needed to better
understand these data.
More severe manic symptoms were unexpectedly
associated with a decreased likelihood of having aTa
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cardiometabolic condition, which remained signiﬁ-
cant in the multivariate models. These data might
be explained by depression having a causal link to
cardiometabolic health (6, 29); more mania in the
last year could reduce the time spent depressed,
therefore reducing the exposure to the depressed
state and the associated cardiometabolic risk. Fur-
thermore, depressed patients may be more likely to
gain weight than manic patients (54). Recent stud-
ies have also shown that increased manic symp-
toms may be correlated with more frequent
exercise, which could also account for this ﬁnding
Table 4. Demographic and clinical variables associated with medical comorbidities (difference of mean and 95% confidence intervals)
Variables
Any Group 1 Any Group 2 Any Group 3
Difference of
means 95% CI
Difference of
means 95% CI
Difference of
means 95% CI
Age (years) at:
Study 7.16b 4.85–9.47 1.61 0.58 to 3.79 3.11c 0.39–5.84
Depression onset 1.84c 0.26–3.42 1.98c 3.41 to 0.54 0.18 1.63 to 1.99
Mania onset 2.65c 0.79–4.51 2.06c 3.76 to 0.35 0.14 2.28 to 2.00
Illness onset 1.79c 0.26–3.32 2.14c 3.53 to 0.75 0.21 1.97 to 1.55
No. lifetime depressive episodesa 1.23 7.08 to 9.53 3.20 4.44 to 10.84 8.37 1.15 to 17.89
No. lifetime manic episodesa 3.14 12.8 to 6.48 4.28 4.56 to 13.12 8.50 2.47 to 19.46
Time spent (years)a:
Depressed 5.35 2.96–7.74 3.46b 1.26–5.66 2.95 0.19–5.71
Manic 4.45 2.07–6.83 3.58c 1.40–5.77 3.19 0.45–5.93
Ill 5.37 2.96–7.79 3.75b 1.52–5.97 3.32 0.52–6.12
CGI-BP score
Overall 0.01 0.16 to 0.18 0.07 0.08 to 0.23 0.28c 0.08–0.47
Mania 0.22 0.46 to 0.03 0.10 0.13 to 0.33 0.24 0.05 to 0.52
Depression 0.23 0.01–0.45 0.10 1.40–5.77 0.30c 0.04–0.55
BISS score
Depression 1.87c 0.42–3.31 0.82 0.51 to 2.14 1.87c 0.22-3.52
Mania 2.43b 3.66 to 1.19 0.14 1.29 to 1.01 1.28 0.15 to 2.71
LIFE-RIFT score 0.64 0.03 to 1.31 0.16 0.78 to 0.45 0.78c 0.02–1.54
BISS = Bipolar Inventory of Symptoms Scale; CGI-BP = Clinical Global Impression Scale for Bipolar Disorder; CI = confidence interval;
LIFE-RIFT = LIFE–Range of Impaired Functioning Tool.
aAnalyses of number of lifetime manic and depressive episodes and numbers of years spent depressed, manic, and ill were adjusted
for age.
bp ≤ 0.001.
cp ≤ 0.05.
Table 5. Association between history of weight-gain medications and metabolic conditions
Meets criteria for:
Overall
Weight-gain medicationsa
p-value
(v2-test)
Yes No
n (%) Total N n (%) Total N n (%) Total N
Hypertension 90 (18.7) 481 20 (19.0) 105 70 (18.6) 376 0.920
Coronary artery disease/myocardial infarction 6 (1.2) 482 1 (1.0) 105 5 (1.3) 377 0.760
Diabetes 30 (6.2) 482 5 (4.8) 105 25 (6.6) 377 0.483
Hyperglycemia 70 (14.5) 482 16 (15.2) 105 54 (14.3) 377 0.814
Hyperlipidemia 103 (21.4) 482 23 (21.9) 105 80 (21.2) 377 0.880
High total cholesterol 61 (12.7) 479 11 (10.7) 103 50 (13.3) 376 0.480
Low HDL cholesterol 157 (32.8) 479 43 (41.7) 103 114 (30.3) 376 0.029
High LDL cholesterol 133 (28.1) 473 27 (26.7) 101 106 (28.5) 372 0.727
Abnormal triglycerides 136 (28.4) 479 45 (43.7) 103 91 (24.2) 376 <0.001
Criteria were based on either medical history or laboratory values. Hyperglycemia was defined as being present if fasting blood glucose
≥100 mg/dL; high total cholesterol if total cholesterol ≥240 mg/dL; low high-density lipoprotein cholesterol (HDL-C) if HDL-C <50 mg/dL
(female) or <40 mg/dL (male); high low-density lipoprotein cholesterol (LDL-C) if LDL-C ≥130 mg/dL; high triglycerides if triglycerides
≥150 mg/dL.
aWeight-gain medications = amitriptyline, aripiprazole, clomipramine, clozapine, doxepin, imipramine, lithium, mirtazepine, olanzapine,
quetiapine, risperidone, and valproate.
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(55, 56). Nearly half of our sample experienced less
than 20% of the previous year in an elevated mood
state; thus, it is also possible that the sample expe-
riencing elevated mood was not large enough for
us to detect an association. Yet, Fiedorowicz and
colleagues found that manic symptoms were asso-
ciated with increased cardiovascular mortality,
independent of cardiovascular risk factors present
at baseline, age, and gender (57).
Finally, medications prescribed for bipolar dis-
order, such as mood stabilizers and antipsychotics,
were associated with low HDL and high triglycer-
ide levels, as expected given that these medications
are typically associated with risk factors for cardio-
vascular disease (30, 31). Yet, other parameters
(e.g., hypertension, hyperlipidemia, and diabetes)
were not associated with these medications. This
may be due to a lack of power given the lower
prevalence of these conditions in our sample,
although the data did not trend in this direction.
Alternatively, providers may be becoming more
conservative in prescribing these medications given
their known deleterious side eﬀects.
Limitations of the current study include relying
on self-report of substance use and Group 2 condi-
tions as well as these data being assessed only at
one time-point which does not allow us to draw
any causal conclusions. Data were collected
through a clinical trial, potentially limiting the gen-
eralizability of the ﬁndings. There may also be
overlap between the groups, as lifetime substance
use predicted the presence of a Group 2 condition.
Of note, the other medical comorbidity group
(Group 2) includes several medical conditions and
thus, the heterogeneity of Group 2 is a potential
limitation. Finally, the lack of a control group lim-
its our ability to discern if these eﬀects are unique
to the bipolar population; however, the ﬁndings
with mania (negative correlation with cardiometa-
bolic conditions and positive correlation with sub-
stance use) do present an important and speciﬁc
relationship with bipolar disorder.
Despite these potential limitations, these data
highlight the substantial medical burden in bipolar
disorder, but perhaps more to the point, that medi-
cal comorbidities could often reﬂect the eﬀects of
the illness and not the conditions themselves. We
hope that, by elucidating the potential interplay
between bipolar disorder and its high medical bur-
den, we will improve the treatment of the disease
(e.g., highlight the need for greater collaboration
between providers, and increase awareness that
depression or age of onset is associated with spe-
ciﬁc medical conditions). This is important as
patients with bipolar disorder are frequently una-
ware of their predisposition for medical comorbidi-
ties and most of the illnesses can be prevented (6,
58). Thus, these data highlight the need to adopt
strategies to reduce medical burden in bipolar dis-
order as well as to integrate medical and psychiat-
ric care for these patients with the aim to improve
overall outcomes.
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